A new duet in cancer biology: AMPK the typical and UBE2O the atypical.
Mol Cell Oncol
; 4(3): e1304846, 2017.
Article
en En
| MEDLINE
| ID: mdl-28616582
ABSTRACT
Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1-hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Mol Cell Oncol
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos